Teva Proposes to Acquire Mylan for $82.00 Per Share in Cash and Stock

Stifel Downgrades Perrigo Co. (PRGO) to Hold

Stifel downgraded Perrigo Co. (NYSE: PRGO) from Buy to Hold.

For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.

Shares of Perrigo Co. closed at $198.08 yesterday.

BMO Capital Upgrades Mylan (MYL) to Market Perform

BMO Capital upgraded Mylan (NASDAQ: MYL) from Underperform to Market Perform with a price target of $75.00 (from $41.00).

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $68.05 yesterday.

Teva Pharma (TEVA) Needs to Raise Mylan (MYL) Bid to $85-$88/Share, Leerink Partners Says

Leerink Partners analyst Jason Gerberry weighed on Teva Pharma (NYSE: TEVA) after the company announced an unsolicited $82/share offer for Mylan (NASDAQ: MYL). The analyst said Teva will likely have to raise its bid to $85-$88 share and even that might not get it done. The analyst said while the deal makes sense, hostile deals carry a low success rate. Despite the comments, the firm... More

Teva Pharma (TEVA) Offers $82/Share for Mylan (MYL)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (Nasdaq: MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company.

Tevas proposal also provides Mylan stockholders with a more... More